Cargando…

Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence

SARS-CoV-2 infection causes COVID-19, which frequently leads to clinical deterioration and/or long-lasting morbidity. Academic and governmental experts throughout the USA met in 2021 to discuss the potential for use of fluvoxamine as early treatment of SARS-CoV-2 infection. Fluvoxamine is a selectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Facente, Shelley N., Reiersen, Angela M., Lenze, Eric J., Boulware, David R., Klausner, Jeffrey D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Current Opinion
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633915/ https://www.ncbi.nlm.nih.gov/pubmed/34851510 http://dx.doi.org/10.1007/s40265-021-01636-5

Ejemplares similares

Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”
por: Lenze, Eric J., et al.
Publicado: (2022)

Repurposing fluvoxamine, and other psychiatric medications, for COVID‐19 and other conditions
por: Lenze, Eric J., et al.
Publicado: (2022)

Fluvoxamine
por: DeVane, C Lindsay
Publicado: (2005)

Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis
por: Lee, Todd C., et al.
Publicado: (2022)

Comment on: “Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence”
por: Mazza, Mario Gennaro, et al.
Publicado: (2022)

Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties
por: Smit, Cornelis, et al.
Publicado: (2020)

Fluvoxamine for the treatment of COVID-19
por: Dodds, Michael G, et al.
Publicado: (2022)

Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective
por: Cohen, Hillel P., et al.
Publicado: (2023)

Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2
por: Fritz, Bradley A., et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Boulware, David R, et al.
Publicado: (2022)

Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
por: Seftel, David, et al.
Publicado: (2021)

Management of obsessive-compulsive disorder with fluvoxamine extended release
por: Ordacgi, Lídia, et al.
Publicado: (2009)

Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies?
por: Speeckaert, Reinhart, et al.
Publicado: (2021)

The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA
por: Baum, Charles, et al.
Publicado: (2015)

Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions
por: Roberts, Melissa H., et al.
Publicado: (2020)

Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
por: Sukhatme, Vikas P., et al.
Publicado: (2021)

An Overview of Fluvoxamine and its Use in SARS-CoV-2 Treatment
por: Arishi, Naif A, et al.
Publicado: (2023)

Medicines Regulation in Africa: Current State and Opportunities
por: Ndomondo-Sigonda, Margareth, et al.
Publicado: (2017)

Clinical Exome Reanalysis: Current Practice and Beyond
por: Ji, Jianling, et al.
Publicado: (2021)

Lipoprotein(a) as a cardiovascular risk factor: current status
por: Nordestgaard, Børge G., et al.
Publicado: (2010)

Current opinions: Zeros in host–parasite food webs: Are they real?()
por: Rossiter, Wayne
Publicado: (2013)

Financing Drug Innovation in the US: Current Framework and Emerging Challenges
por: Cutler, David, et al.
Publicado: (2020)

Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2
por: Tonk, Miray, et al.
Publicado: (2021)

Effect of Sacubitril/Valsartan on Neurocognitive Function: Current Status and Future Directions
por: Galo, Jason, et al.
Publicado: (2020)

Epigenetics and ADHD: Reflections on Current Knowledge, Research Priorities and Translational Potential
por: Cecil, Charlotte A. M., et al.
Publicado: (2022)

Confusion: Acetaminophen Dosing Changes Based on NO Evidence in Adults
por: Krenzelok, Edward P., et al.
Publicado: (2012)

Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis
por: Corrado, Domenico, et al.
Publicado: (2020)

The Current State of Subjective Training Load Monitoring: Follow-Up and Future Directions
por: Coyne, Joseph O. C., et al.
Publicado: (2022)

Pain in Intellectually Disabled Children: Towards Evidence-Based Pharmacotherapy?
por: Valkenburg, Abraham J., et al.
Publicado: (2015)

The Current State of Subjective Training Load Monitoring—a Practical Perspective and Call to Action
por: Coyne, Joseph O. C., et al.
Publicado: (2018)

Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure
por: Bavendiek, Udo, et al.
Publicado: (2017)

Review of evidence on using ACEi and ARBs in patients with hypertension and COVID-19
por: Khan, Sikandar Hayat, et al.
Publicado: (2020)

The evidence remains clear: SARS-CoV-2 emerged via the wildlife trade
por: Garry, Robert F.
Publicado: (2022)

Current Challenges in Labelling for Generic Medicinal Products: Company Core Data Sheet (CCDS) Development and Maintenance
por: Mueller, Marion, et al.
Publicado: (2020)

Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges
por: Sagili Anthony, Deva Priya, et al.
Publicado: (2021)

Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines
por: Sultana, Janet, et al.
Publicado: (2020)

Personalized, Evidence-Informed Training Plans and Exercise Prescriptions for Performance, Fitness and Health
por: Wackerhage, Henning, et al.
Publicado: (2021)

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
por: Husereau, Don, et al.
Publicado: (2018)

Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials
por: Paliard, Xavier, et al.
Publicado: (2019)

From a Technology That Replaces Human Perception–Action to One That Expands It: Some Critiques of Current Technology Use in Sport
por: Woods, Carl T., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jatp472v3kv42b46a9ddnis8vv